Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721871 · ClinicalTrials.gov registry record · Phase 2
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
A Phase 2 study of Rare Diseases and Congenital Disorders, sponsored by Napo Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT06721871 is a Phase 2 study of Rare Diseases and Congenital Disorders that is actively recruiting participants, run by Napo Pharmaceuticals. The registered enrollment target is 12 participants, below the 17,474-participant average among 7 other Rare Diseases trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06721871, a Phase 2 study of Rare Diseases and Congenital Disorders, is actively recruiting participants, sponsored by Napo Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
a 32-week study that will evaluate the safety, tolerability and preliminary efficacy of multiple ascending doses of crofelemer, compared to placebo, using a randomized cross-over design within each dose level, when administered to participants with MVID receiving parenteral support (PS, defined as TPN with or without supplementary IV fluid requirements). Blinded study drug will be administered as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution. Assigned study drug will be reconstituted and administered orally (or enterally) three times daily (TID) as a concentrated liquid formulation in each of the three dose levels
Conditions Studied
Interventions
- DRUG Crofelemer Powder for Oral Solution
- DRUG Placebo Powder for Oral Solution
Study Locations (3)
Other
- UOS Gastroenterolgia e Riabilitazione nutrizionale Piazza Sant' Onofrio 4 - Rome
- Al Jalila Children's Hospital - Dubai
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06721871
The ClinicalTrials.gov registry entry for NCT06721871 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 17,474-participant average among 7 other Rare Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Napo Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Rare Diseases appearing as the primary indexed condition, and to 2 interventions - of which Crofelemer Powder for Oral Solution is the first listed.
NCT06721871 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06721871 about?
NCT06721871 is a clinical study titled "Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)". a 32-week study that will evaluate the safety, tolerability and preliminary efficacy of multiple ascending doses of crofelemer, compared to placebo, using a randomized cross-over design within each dose level, when administered to participants with MVID receiving parenteral support (PS, defined as T...
What is the current status of trial NCT06721871?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2025-05-01. Estimated completion is 2026-03.
What conditions does trial NCT06721871 study?
This clinical trial studies the following conditions: Rare Diseases, Congenital Disorders, Microvillus Inclusion Disease.
What interventions are being tested in trial NCT06721871?
The interventions under investigation include: Crofelemer Powder for Oral Solution (DRUG), Placebo Powder for Oral Solution (DRUG).
Who is sponsoring clinical trial NCT06721871?
This trial is sponsored by Napo Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721871 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rare Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Studies of Patient With FPDMM
RECRUITING
-
Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas
RECRUITING · NA
-
Baker Gordon Syndrome Natural History Study
RECRUITING
-
UW Undiagnosed Genetic Diseases Program
RECRUITING
-
A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
RECRUITING
-
Epilepsy Learning Healthcare System (ELHS)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.